Related Experiment Video

Updated: Jul 4, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides

Xiu-Min Zhang1, Yun-Fei Zhang, Yang Huang

  • 1State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital, Fourth Military Medical University, Shaanxi Province 710032, P.R. China.

Oncology Reports
|June 26, 2008
PubMed

Insights

Combining MAGE-3 and MAGE-n tumor antigens in a polyvalent cancer vaccine enhances anti-tumor immune responses. This approach may offer a more effective peptide-based immunotherapy strategy for hepatocellular carcinoma (HCC).

Area of Science:

  • Immunology
  • Oncology
  • Vaccine Development

Background:

  • Tumor antigen-derived peptides are crucial for eliciting tumor-specific cytotoxic T lymphocytes (CTLs).
  • MAGE gene products, including MAGE-3 and the novel MAGE-n, are implicated in various cancers like hepatocellular carcinoma (HCC).
  • Previous single-antigen peptide vaccines have limitations due to heterogeneous tumor antigen expression.

Purpose of the Study:

  • To investigate the efficacy of a polyvalent cancer vaccine combining MAGE-3 and MAGE-n derived peptides.
  • To compare the anti-tumor immune response induced by the combined vaccine versus single-peptide vaccines.
  • To explore the potential of multi-antigen peptide vaccines for improved cancer immunotherapy.

Main Methods:

  • Development of a polyvalent cancer vaccine incorporating MAGE-3 and MAGE-n derived peptides.
  • Evaluation of the anti-tumor immune responses induced by the combined peptide vaccine.
  • Assessment of peptide-specific activity in an MHC-restricted manner.

Main Results:

  • The combination of MAGE-3 and MAGE-n epitopes induced significantly more effective anti-tumor immune responses compared to individual peptides.
  • Peptide-specific activity was confirmed to be MHC-restricted.
  • The polyvalent vaccine demonstrated enhanced efficacy in eliciting tumor-specific CTL responses.

Conclusions:

  • A polyvalent vaccine combining MAGE-3 and MAGE-n derived peptides offers a promising strategy for cancer immunotherapy.
  • Multi-antigen peptide vaccines may overcome the limitations of single-antigen vaccines by addressing tumor heterogeneity.
  • This approach holds potential for more effective peptide-based cancer treatment, particularly for HCC.

More Related Videos

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants10:44

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.